6月2日，科伦博泰生物盘中下跌6.11%，报412.4港元，成交额2484.81万港元。
消息面上，近期科伦系"三驾马车"业绩全面失速的报道持续发酵，科伦博泰虽营收增长6.5%至20.58亿元，但净亏损扩大至3.82亿元，授权及里程碑收入大幅减少、研发费用高企是主因。与此同时，港交所披露显示，董事长刘革新于5月26日至28日连续减持合计约25.73万股，进一步加剧市场担忧情绪。此前该股因ASCO年会临床数据利好及野村上调目标价至544.42港元等催化连续上涨，积累了较多获利盘。在基本面"增收不增利"与高管减持的双重压力下，短期资金选择获利了结，对股价形成持续压力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.